Obesity is a growing global health concern, often leading to serious conditions such as hypertension, type 2 diabetes, and cardiovascular diseases. The imbalance between energy intake and metabolism is a primary cause of obesity. However, emerging research suggests that probiotics, like Bifidobacterium longum subsp. longum BL21 (BL21), can play a crucial role in regulating intestinal flora, thereby inhibiting obesity and improving metabolic disorders.   Wecare Probiotics Co., Ltd., a national high-tech enterprise, is at the forefront of this research. Specializing in the development and application of probiotic strains, the company offers a range of products including bifidobacterium probiotic powder, which is gaining attention for its health benefits.   Introduction This study used the Bifidobacterium longum subsp. longum BL21 to intervene in high-fat feed induced obese mice, exploring the effect of BL21 on obese mice, providing efficacy support for BL21 in controlling weight, lowering blood lipids, and regulating intestinal microbiota.   Study Design     Main Results BL21 attenuated weight gain   Total Cholesterol   Triglycerides   Low-density lipoprotein cholesterol   BL21 showed the lipid-lowering activity   BL21 ameliorated fat vacuolization in liver cells and epididymal fat accumulate ion, protected liver.   BL21 restored the gut microbiota diversity Restored F/B Increased Akkermansia BL21 regulated the gut microbiota disorder   Conclusion： Continuous intervention with BL21 (1 B CFU/d for 8 weeks can effectively suppress obesity caused by a high-fat diet BL21 has lipid-lowering activity and balancing intestinal effect.   Wecare Probiotics Co., Ltd. is committed to leveraging the power of probiotics like Bifidobacterium Longum BL21 to enhance human health. With a focus on quality and innovation, the company continues to develop effective probiotic solutions for various fields, including food, health food, precision medicine, and more.   For those seeking natural ways to combat obesity and improve metabolic health, Bifidobacterium Longum BL21, backed by Wecare Probiotics' expertise, offers a promising solution.

Bifidobacterium longum subsp. longum Remodeled Roseburia and Phosphatidylserine Levels, Ameliorated Intestinal Disorders and liver Metabolic Abnormalities Induced by High-Fat Diet

Obesity is a growing global health concern, often leading to serious conditions such as hypertension, type 2 diabetes, and cardiovascular diseases. The imbalance between energy intake and metabolism is a primary cause of obesity. However, emerging research suggests that probiotics, like Bifidobacterium longum subsp. longum BL21 (BL21), can play a crucial role in regulating intestinal...

Abstract: This patent discloses a probiotic composition aimed at alleviating depressive and anxiety behaviors. The composition consists of two probiotic strains: Bifidobacterium longum subsp. longum BL11 and Lacticaseibacillus casei LC89. The combination of these strains has been found to synergistically improve the efficacy in alleviating depressive or anxiety-related behaviors when compared to the use of a single strain. Background: Depression and anxiety are common mental health disorders influenced by various factors, including stress and health conditions. Traditional antidepressant medications, while effective, have side effects such as nausea, headaches, and sexual dysfunction. Probiotics offer a promising alternative, as they can modulate gut microbiota, which is intricately linked to mental health through the gut-brain axis. This invention seeks to develop a safer, more effective probiotic solution for preventing and managing depression and anxiety. Claims: 1. Probiotic Composition:The probiotic composition comprises Bifidobacterium longum subsp. longum BL11 (CGMCC No. 24412) and Lactobacillus casei LC89 (CGMCC No. 15409), with ratios ranging from 1:20 to 20:1 of viable cells. 2. Probiotic Preparation:The probiotic preparation can include freeze-dried powders, capsules, tablets, or granules with a total viable count not less than 1×10⁹ CFU per mL or g. 3. Application:The composition is intended for the preparation of products aimed at preventing, improving, or treating depressive or anxiety disorders. The final product may include excipients like binders or functional agents such as prebiotics (e.g., inulin, FOS). Experimental Evidence: The patent outlines several experiments demonstrating the effectiveness of the probiotic combination in alleviating depressive and anxiety-like behaviors in mice: 1. Forced Swim Test:The combination of BL11 and LC89 significantly reduced immobility time in mice, indicating decreased depressive behavior. 2. Tail Suspension Test:Similar to the swim test, probiotic intervention led to less immobility, suggesting a reduction in depressive symptoms. 3. Elevated Plus Maze and Jump Test:Mice treated with the probiotics showed increased time spent in the open arms of the maze, reflecting reduced anxiety. Conclusion: This invention provides an innovative probiotic composition that enhances the therapeutic effects on depressive and anxiety behaviors. The synergy between Bifidobacterium longum subsp. longum BL11 and Lacticaseibacillus casei LC89 offers a novel, safe approach for managing mental health disorders through gut microbiota modulation.

WecMix™ Probiotic Formulation Containing in Alleviating Depressive or Anxiety Behaviors

Abstract: This patent discloses a probiotic composition aimed at alleviating depressive and anxiety behaviors. The composition consists of two probiotic strains: Bifidobacterium longum subsp. longum BL11 and Lacticaseibacillus casei LC89. The combination of these strains has been found to synergistically improve the efficacy in alleviating depressive or anxiety-related behaviors...